Journal of Clinical Oncology
Articles in this Issue
Efficacy and safety of serplulimab-based therapy in HER2-negative advanced gastric cancer: A real-world study.
e16031 Background: Serplulimab is an anti-PD-1 inhibitor demonstrating promising anti-tumor activity and is recommended for the treatment of microsatellit...
Differences in genomic profiles, targeted treatment use, and overall survival in patients with metastatic breast cancer by Area Deprivation Index.
1046 Background: We previously showed racial differences in circulating tumor DNA (ctDNA) profiles and PI3K inhibitor (PI3Ki) use in patients (pts) with m...
Prognostic features and clinical panthological factors of mucosal malignant melanoma.
e21588 Background: Mucosal malignant melanoma (MMM) is a rare subtype occurring in sites like the gastrointestinal and respiratory tracts. This study aims...
Physician-patient communication and shared decision-making approaches in myeloproliferative neoplasm care.
e18589 Background: About 20,000 people are diagnosed with Myeloproliferative Neoplasms (MPNs) in the US each year, and almost 300,000 have the disease. Ag...
Real-world treatment utilization patterns, discontinuation and healthcare resource utilization of first-line (1L) bruton tyrosine kinase inhibitor (BTKi) therapy in chronic lymphocytic leukemia (CLL): Age-related disparity.
e19033 Background: CLL tends to affect older individuals, and older patients often endure greater health disparities and treatment burdens that may impact...
Management and outcomes of rash, peripheral neuropathy (PN), and hyperglycemia (HG) during first-line (1L) treatment (tx) of locally advanced/metastatic urothelial cancer (la/mUC) in a real-world setting.
e23275 Background: Real-world data on adverse events (AEs) among contemporary 1L Tx regimens for la/mUC are limited. Rash, PN, and HG are potential dose-l...
Performance analysis of artificial intelligence–driven convolutional neural network architectures for liver tumor segmentation.
e16307 Background: Advances in medical image segmentation have raised debate about the practical performance of the latest architectures and CNN-based app...
A phase 1 study of the OX40 agonist BGB-A445, with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced NSCLC, HNSCC, or NPC.
2525 Background: BGB-A445 is a monoclonal antibody OX40 agonist that does not compete with the natural OX40 ligand, reducing the likelihood of a hook effe...
Comparing in-hospital outcomes between total parenteral nutrition and enteral feeding in esophageal and gastric cancer: A nationwide analysis.
e16086 Background: Patients with gastric and esophageal cancer (GEC) may experience significant dysphagia resulting in malnutrition and weight loss. Nutri...
Long-term outcomes and overall survival (OS) for zanidatamab + chemotherapy in HER2-positive (HER2+) advanced or metastatic gastroesophageal adenocarcinoma (mGEA): 4-year follow-up of a phase 2 trial.
4013 Background: Zanidatamab (zani), a dual HER2-targeted bispecific antibody, plus chemotherapy (chemo) has previously demonstrated antitumor activity an...
Clinical utility and cost-effectiveness of a molecular biomarker for immune checkpoint inhibitor response monitoring and treatment decisions.
e23338 Background: Clinical validation studies have shown that response using ctDNA may detect treatment response following immune checkpoint inhibitor th...
Should toxicity be taken into account in determining chemotherapy backbone in HER2-positive (HER2+) early breast cancer (eBC)?
e12628 Background: Trastuzumab-Pertuzumab (TP) plus chemotherapy is the standard of care in stage II-III HER2+ eBC, but guidelines give general recommenda...
Immunologic targeting of native and mutated ESR1 receptor for treatment of hormone receptor expressing metastatic breast cancer.
TPS1132 Background: Hormone receptor positive (HR+) HER2 negative metastatic breast cancer (MBC) remains a difficult clinical problem. Endocrine therapies...
Performance of Aspyre Lung on cytology specimens.
e15069 Background: For patients with Non-Small Cell Lung Cancer (NSCLC), testing for actionable variants is essential to guiding therapeutic treatment pla...
Updated results of camrelizumab (Cam) plus low dose apatinib combined with gemcitabine and cisplatin (GP) as first-line therapy for advanced biliary tract cancer (BTC): A single center, phase Ib/II trial.
e16202 Background: Combination of PD-1/PD-L1 with GP has been the standard regimen for advanced biliary tract cancer (aBTC). Apatinib, an oral TKI selecti...
Efficacy analysis of neoadjuvant PD-1 inhibitor combined with chemotherapy in various subanatomical sites of locally advanced and recurrent resectable head and neck squamous cell carcinoma: A retrospective real-world study.
6067 Background: Clinical research on Head and Neck Squamous Cell Carcinoma (HNSCC) often considers the disease as a whole. However, the therapeutic outco...
Dermatologic prophylaxis and impact on patient-reported outcomes in first-line <i>EGFR</i> -mutant advanced NSCLC treated with amivantamab plus lazertinib: Results from the phase 2 COCOON trial.
8641 Background: The phase 2 COCOONtrial (NCT06120140) is evaluating the impact of enhanced dermatologic management (DM) in combination with amivantamab (...
Real-world outcomes among patients with metastatic castration-resistant prostate cancer (mCRPC) receiving guideline-recommended therapies after treatment with <sup>177</sup> Lu-PSMA-617: A real-world prostate cancer disease observation (PRECISION) data platform analysis.
e17035 Background: 177 Lu-PSMA-617 was approved in March 2022 for patients with mCRPC pretreated with an androgen receptor pathway inhibitor (...
Cellular proliferation and tumor suppression pathways as potential targets in clinically aggressive sarcomas.
e23551 Background: Sarcomas are rare, heterogeneous, and aggressive malignancies with poor prognosis, driven by dysregulated proliferation pathways (e.g.,...
Real-world pharmacovigilance study of myelotoxicity with PARP inhibitors in breast and ovarian malignancies.
e23299 Background: Poly ADP-ribose polymerase inhibitors (PARPi) revolutionized the management of BRCA1/2-mutated breast and ovarian cancers by targeting...
Phase 2 study of MK-3475A in relapsed or refractory classic Hodgkin lymphoma or primary mediastinal large B-cell lymphoma.
TPS7090 Background: The PD-1 inhibitor pembrolizumab is approved globally for the treatment of multiple cancers, including relapsed or refractory (R/R) cl...
DNA damage measurements as a potential biomarker for immunotherapy response in ovarian cancer.
e17600 Background: Ovarian cancer patient outcomes are linked with DNA repair defects and damage within the tumor. In this study, we tested the Repair Ass...
Investigating ctDNA testing in breast cancer and its connection to stress and anxiety.
e12540 Background: Molecular residual disease (MRD) assessment in breast cancer by circulating tumor DNA (ctDNA) has shown great promise in predicting rec...
Efficacy and safety results of a multi-center phase II study of utidelone injection in combination with PD-1 inhibitor and chemotherapy for the first-line treatment of advanced gastric and esophagus cancers.
4040 Background: Utidelone is a novel microtubule inhibitor that offers several advantages including improved efficacy and safety, broader anti-cancer spe...
Incidence of colorectal cancer in the republic of Ireland: Trends and challenges.
e15696 Background: The incidence of early onset colorectal cancer (EOCRC; ≤50 years) is increasing globally, while the incidence of average onset colorect...